CurrentBlue Cross Blue Shield - IowaPolicy 05.02.71

Oral Vancomycin Quantity Limit

Defines quantity limits for oral vancomycin products (Vancocin capsules and Firvanq oral solution) for treatment of C. difficile-associated diarrhea and staphylococcal enterocolitis for Wellmark/Blue Cross Blue Shield members.

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyOral Vancomycin Quantity Limit

Policy CodePolicy 05.02.71

Change TypeNo material change

Effective DateMay 16, 2019

Next Review DateAug 1, 2025

Key ActionEnsure dispensed quantity does not exceed the stated quantity limits at point of dispensing to avoid claim rejection.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

80Vancocin quantity limit

450Firvanq initial limit (mL)

10Standard course (days)

no limitAnnual fills for recurrent CDI

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Standard adult CDI or staphylococcal enterocolitis course: Dispensed quantity up to 80 Vancocin capsules OR up to 450 mL Firvanq solution to accommodate a 10-day standard course (125 mg PO QID for 10 days)<=80 capsules OR <=450 mL

Supports standard 10-day regimens

Tapered/pulsed and recurrence regimens: Quantity limits also account for tapered/pulsed regimens and treatment of recurrences; maximum pulse regimen may equate to greater quantities (e.g., up to 105 units of 125 mg capsules or equivalent mL of solution)may require > initial limit across fills

Policy allows fulfillment across multiple fills; claims exceeding the initial dispensing limit will reject at point of fill and additional fills may be provided to complete tapered/pulse regimens or recurrent CDI therapy; no annual limit on number of fills for recurrent CDI

Orally administered vancomycin products are indicated for gastrointestinal infections caused by susceptible organisms and are not effective when given parenterally for those indications; therefore, oral formulations must be used for these infections. Specifically, oral vancomycin should be limited to treatment of proven or strongly suspected gastrointestinal infections for which the product is indicated, and it is not effective for infections outside of Clostridioides difficile-associated diarrhea and staphylococcal enterocolitis.

Use of oral vancomycin for indications other than those supported by the product labeling is not endorsed. The labeling states that orally administered vancomycin is not effective for other types of infections, and the agent should be reserved for infections that are proven or strongly suspected to be caused by susceptible bacteria.

Provider Actions & Dispensing Rules

Billing Rule

Quantity limits and clinical regimens

The quantity limit for oral vancomycin (Vancocin) is set to accommodate standard treatment courses: up to 80 capsules (125 mg strength) or up to 450 mL of Firvanq (50 mg/mL) to cover a 10-day standard course. Tapered/pulsed regimens and adjunctive rifaximin for recurrences are recognized clinical practices; pulse/taper regimens with larger total quantities may be filled across multiple dispensings, and the initial quantity limit is set at each 10-day dispensing interval so that treatment courses using 125 mg capsules or 25 mg/mL solution can generally be fulfilled in two or fewer fills. No annual fill limit is applied for recurrent CDI — additional courses may be dispensed as clinically indicated for recurrences. If a patient requests more than the initial quantity limit at the time of dispensing, the claim will reject with a message indicating that quantity limits are exceeded.

Guideline-recommended regimens supported: 125 mg PO QID ×10 days for initial and first recurrent CDI; tapered/pulsed vancomycin regimens and rifaximin adjunctive therapy for subsequent recurrences are acceptable.
Quantity limits: 80 × 125 mg capsules OR 450 mL of 50 mg/mL solution per initial dispensing (10-day standard course).
No annual fill limit for recurrent CDI — additional courses covered when clinically indicated.

Billing Rule

Billing and coding expectations

Report provider services using appropriate procedure and diagnosis coding on claims. Use CPT, HCPCS (alpha-numeric), Revenue, and ICD-10 diagnostic codes as applicable for the encounter and services rendered. Ensure coding reflects the indication (e.g., Clostridioides difficile infection) and any procedures or site-of-care specifics per standard billing practice to support medical necessity.

Include relevant ICD-10 code(s) supporting CDI diagnosis on the claim.
Use applicable CPT/HCPCS for services (office visit, infusion, specimen collection, etc.) and appropriate revenue codes for facility billing.

Background

Oral vancomycin formulations (e.g., Vancocin capsules and oral solution) are indicated for treatment of Clostridioides difficile-associated diarrhea and staphylococcal enterocolitis of the gastrointestinal tract. The product labeling emphasizes that parenteral vancomycin is not effective for these infections and that oral administration is required. To limit resistance and preserve effectiveness, oral vancomycin should be used only for infections proven or strongly suspected to be caused by susceptible bacteria, with culture and susceptibility data or local epidemiology guiding therapy when available.

Definitions

Vancocin — Key facts

DrugVancocin (vancomycin oral capsules)

IndicationTreatment of Clostridioides difficile-associated diarrhea

Additional indicationTreatment of enterocolitis caused by Staphylococcus aureus (including MRSA)

Standard quantity limit80 capsules to accommodate a 10-day standard course (125 mg PO QID)

Note on administrationOral formulation required — parenteral vancomycin is not effective for these infections

Firvanq — Key facts

DrugFirvanq (vancomycin oral solution)

IndicationTreatment of Clostridioides difficile-associated diarrhea in adults and pediatric patients

Additional indicationTreatment of enterocolitis caused by Staphylococcus aureus (including MRSA) in adults and pediatric patients

Standard quantity limit450 mL initial quantity limit to accommodate a 10-day standard course (125 mg PO QID)

Antibiotic stewardshipUse only to treat or prevent infections proven or strongly suspected to be caused by susceptible bacteria; consider culture/susceptibility and local epidemiology